Complex role of RhoA in regulating vascular smooth muscle cell phenotypes in type 2 diabetes

Yaw Asare-Amankwah, Kirsten Riches-Suman

Cardiovascular Research Group, School of Chemistry and Biosciences, University of Bradford, Bradford BD7 1DP, UK.

Correspondence to: Dr. Kirsten Riches-Suman, Cardiovascular Research Group, School of Chemistry and Biosciences, University of Bradford, Richmond Road, Bradford BD7 1DP, UK. E-mail: k.riches@bradford.ac.uk

How to cite this article: Asare-Amankwah Y, Riches-Suman K. Complex role of RhoA in regulating vascular smooth muscle cell phenotypes in type 2 diabetes. Vessel Plus 2022;6:64. https://dx.doi.org/10.20517/2574-1209.2022.26

Received: 4 May 2022 First Decision: 10 Aug 2022 Revised: 17 Aug 2022 Accepted: 16 Sep 2022 Published: 16 Dec 2022

Academic Editors: Yajing Wang, Alexander D. Verin Copy Editor: Peng-juan Wen Production Editor: Peng-juan Wen

Abstract

The incidence of type 2 diabetes mellitus (T2DM) is growing globally, and the major cause of morbidity and mortality in these patients is the premature development of cardiovascular disease. Consequently, medical interventions, such as coronary artery bypass graft surgery and widespread statin prescriptions, are common in this patient group. Smooth muscle cells are the major structural component of the vascular wall. They play a crucial role in post-bypass recovery to successfully revascularize the heart by switching between differentiated (contractile) and dedifferentiated (synthetic) phenotypes. However, in patients with T2DM, these cells have functional defects that may affect bypass integration. RhoA is a small GTPase that regulates many functions, such as motility and phenotypic regulation of smooth muscle cells. RhoA is dependent upon a stimulus, and it can drive the contractile smooth muscle cell phenotype present in the healthy condition or the (mal)adaptive phenotypes prevalent in disease or in response to injury. We hypothesize that RhoA deregulation plays a major role in vascular complications of T2DM. This protein is deregulated in T2DM smooth muscle cells, which may in part explain the functional defects of smooth muscle tissue and the subsequent failure rate of bypass in these patients. An important consideration in this circumstance is the use of statin therapies because these further inhibit RhoA activity. The effect of inhibition of RhoA activity in patients with T2DM who have a bypass is currently unknown.

Keywords: Type 2 diabetes, smooth muscle cell, phenotype, RhoA, contractile, synthetic, statins
INTRODUCTION

The incidence of type 2 diabetes mellitus (T2DM) is escalating at an alarming rate, and 7% of people worldwide are expected to suffer from T2DM within the next decade\(^1\). The leading cause of morbidity and mortality in these patients is the premature development of microvascular and macrovascular complications, such as extensive atherosclerotic lesions leading to heart attacks, stroke and peripheral artery disease\(^2\). Smooth muscle cells (SMCs) are the principal cell type in the vascular wall. Therefore, understanding how these cells behave and respond to challenges in T2DM is critical for the development of new therapeutic avenues that are required to address this global crisis. This review article examines the hypothesis that RhoA is an attractive target for improving vascular health in diabetes through its actions in SMCs.

SMCs are contractile and have inherent plasticity and ability to dedifferentiate into a number of phenotypes to maintain vessel function following a challenge. This is an important adaptation in response to injury, disease or age. However, this adaptation can quickly become maladaptive if the exquisite sensitivity to phenotypic cues is lost\(^3\). The molecular pathways controlling the SMC phenotype are well recognized. The serum-response factor (SRF) - myocardin signaling axis is a major determinant of SMC differentiation. Under normal healthy conditions, myocardin and myocardin-related transcription factors (MRTF-A and MRTF-B) are shuttled from the cytoplasm into the nucleus where they associate with SRF. Once combined, these complexes bind as transcription factors to areas of the genome containing CARG cis elements (CC(A/T)GG). This binding increases the expression of classical contractile SMC markers, such as alpha smooth muscle actin (\(\alpha\)-SMA; ACTA2), smooth muscle myosin heavy chain, smooth muscle 22 alpha, calponin and smoothelin\(^4\). These proteins play structural roles in SMC contraction and maintain vessel homeostasis.

In aging, repair or disease, SMCs transiently adopt a synthetic phenotype. External cues, such as platelet-derived growth factor-BB (PDGF-BB), upregulate Kruppel-like factor 4 (KLF4) expression. This protein has an inverse relationship with myocardin and, when expressed at high levels, inhibits myocardin, which is no longer available as a co-factor for SRF. Therefore, the expression of contractile machinery falls. KLF4 also upregulates pro-inflammatory nuclear factor kappa B (NF\(\kappa\)B) signaling and SMC dedifferentiation\(^5\). However, there is no definitive “SMC” phenotype. The SMC phenotype exists along a spectrum from contractile to synthetic, and is fluid regarding protein expression and ion channel types across different vessels. Furthermore, synthetic SMCs can reacquire a contractile phenotype, which is referred to as redifferentiation\(^6\)\(^-\)\(^8\), indicating that phenotypic switching can occur in both directions.

Delineating these pathways is important for understanding the functional differences in healthy or diseased/aged blood vessels. Contractile SMCs, as the name suggests, contract and relax in response to biological cues to maintain vascular tone. Synthetic SMCs proliferate and migrate into the intima, which contributes to neointimal hyperplasia, progression of atherosclerosis, coronary microvascular dysfunction and many other pathologies. Therefore, identifying defective signaling pathways in SMCs that could be targeted by new or re-purposed therapies will have a major effect on global health, and societal and financial costs.

RhoA

RhoA is a member of the Rho subfamily of GTPases and has diverse roles within the cell, such as the regulation of morphology, cytoskeletal arrangement and migration. Recently recognized roles of RhoA are transcriptional control, reactive oxygen species production and the DNA damage response pathway in a cell-dependent context\(^9\)\(^-\)\(^11\). RhoA is post-translationally modified by the addition of geranylgeranyl
pyrophosphate at the carboxyl terminus. The attachment of this moiety renders the protein lipophilic, and it is transported to cellular membranes to carry out its role \[12\].

**Regulation of RhoA**

Once in the membrane, the activity of RhoA is tightly controlled by a number of activatory and inhibitory mechanisms. Therefore, RhoA acts as a molecular switch cycling between an inactive guanosine diphosphate (GDP)-bound and an active guanosine triphosphate (GTP)-bound conformation, allowing interactions with downstream targets to trigger a cascade of cellular responses \[13\]. This tight regulation is important because over-activation of Rho proteins results in the pathogenesis of several cardiovascular disorders \[14\]. A combination of regulatory proteins is responsible for mediating RhoA activity, such as Rho guanine exchange factors (GEFs), GTPase-activating proteins (GAPs) and GDP dissociation inhibitors (GDIs).

**GEFs**

RhoGEFs promote GDP/GTP exchange to enable the formation of active GTP-bound RhoA \[15\]. A number of RhoGEFs have been identified as susceptibility genes for cardiovascular disorders. The role of RhoGEFs, specifically leukemia-associated Rho GEF, PDZ domain-containing RhoGEF and p115 RhoGEF, in activating Rho proteins allows for the modulation of vascular tone, particularly in hypertension \[16\]. GEF-H1, which is a RhoA-specific GEF associated with cytoskeletal structure, microtubules and actin cytoskeletal regulation, induces the activation of RhoA. In SMCs, p115 RhoGEF and GEF-H1 promote SMC proliferation \[17\]. The dual nature of RhoA activation, where it can promote both differentiation and dedifferentiation, is discussed in the “RhoA and SMC phenotype” section below.

**GAPs**

RhoGAPs are negative regulators of RhoA \[18\] and are responsible for increasing or stimulating the hydrolysis of RhoGTPases. RhoGAPs trigger the intrinsic GTPase activity that RhoA possesses to hydrolyze the bound GTP back into GDP, switching off the signaling mechanism \[19\]. Even though RhoGAPs are widely expressed, each of them plays a specialized role, and they regulate RhoGTPase signals spatially and temporally by detecting their expression patterns, domain structures and potential protein interactions \[20\]. RhoA is targeted specifically by p122RhoGAP and RARhoGAP \[20\]. Additionally, in SMCs, RhoA can trigger RhoA/Rho kinase (ROCK)-dependent inhibition of myosin phosphatase and subsequent cellular migration \[21-24\].

**GDIs**

RhoGDIs sequester RhoA in the cytoplasm. RhoGDIs prevent the correct localization of RhoA to cellular membranes, and also prevent the dissociation of GDP from RhoA, ensuring that GTP cannot bind and trigger the signaling cascade. RhoGDIs act to couple the nucleotide cycle of the Rho family GTPases to a membrane cycle with localized G protein for signaling \[25\]. There are three isoforms for RhoGDIs, namely RhoGD11, RhoGD12 and RhoGD13, and the former two are cytosolic and the latter is non-cytosolic \[26\]. RhoGDIs appear to lack specific sequences that confer direct membrane association \[27\]. However, they are still considered an important target for druggable therapeutics within signaling mechanisms controlled by G proteins, and inhibiting RhoGDIs could have profound effects on cellular activity \[28\].

**MicroRNAs**

While RhoGEFs, GAPs and GDIs act at the post-translational level, RhoA can also be regulated at the post-transcriptional level by microRNAs (miRNAs). These short, non-coding RNAs are associated with cardiovascular diseases and SMC phenotypic switching \[29\]. They negatively regulate target protein
translation by binding to mRNA and targeting it for degradation. A number of miRNAs are known to target RhoA mRNA, such as miR-31, miR-200b and miR-340\textsuperscript{[30-33]}. Therefore, these miRNAs can inhibit the RhoA signaling pathway by reducing the absolute amount of RhoA present within a cell instead of regulating its activity level. A comprehensive understanding of RhoA-targeting miRs specifically in vascular SMCs has yet to be achieved. However, miR-133a and miR-141\textsuperscript{[34,35]} have been validated in a number of vascular SMC types, and most recently, miR-145 has been suggested to regulate RhoA\textsuperscript{[36]}. Whether this is a direct or indirect targeting remains to be determined, but because of the importance of miR-145 in regulating the SMC phenotype and function\textsuperscript{[39]}, this is worthy of further investigation.

A summary of the various RhoA regulatory mechanisms is shown in Figure 1.

**RhoA AND SMC PHENOTYPE**

Because of the critical role that RhoA plays in regulating morphology, migration and the cytoskeleton, alterations in RhoA activity will inevitably have an effect on SMC biology. However, the manner in which RhoA has an effect - through contractility or migration - remains controversial and is dependent upon a stimulus. The principal effector proteins of the RhoA signaling pathway are the ROCKs.

The ROCKs are serine/threonine kinases and consist of two isoforms, namely ROCK1 (also known as ROCK-beta or p160 ROCK) and ROCK2 (also known as ROCK-alpha or p150 ROCK)\textsuperscript{[37-39]}. ROCK1 and ROCK2 share a similar structure with 92% homology in their kinase domains. They also share pleckstrin-homology domains, which enable protein interactions, and carboxy-terminal domains, which act as auto-inhibitors to regulate their kinase activity\textsuperscript{[21]}. Active GTP-bound RhoA binds to the Rho-binding domain in ROCKs to induce a conformational change in the protein, which allows it to phosphorylate downstream effectors\textsuperscript{[40]}.

Both ROCK isoforms are expressed ubiquitously in invertebrates and vertebrates. However, within the vasculature, ROCK2 expression is proportionally higher in vascular endothelial cells and SMCs, and ROCK1 is the dominant isoform in circulatory inflammatory cells\textsuperscript{[41,42]}. Nonetheless, many studies have focused on the ROCK1 isoform and its critical role in stress fiber and focal adhesion formation, as well as SMC contraction\textsuperscript{[43]}. Promotion of the contractile (differentiated) SMC phenotype

RhoA/ROCK promotes the contractile SMC phenotype through the stabilization of actin stress fibers. These fibers are composed of actin filaments held together by the actin crosslinking protein α-actinin and are responsible for maintaining cell shape and adhesion. Actin stress fibers are essential in mediating cell migration and interactions with the environment\textsuperscript{[44]}. RhoA can be activated by transforming growth factor beta (TGFβ; a well-recognized differentiation stimulus) or G protein-coupled receptors and signals through the ROCK and mammalian diaphanous-related formin pathways to promote stress fiber formation. ROCKs can directly activate myosin light chain kinase to stabilize stress fibers. ROCKs also stimulate LIM kinase to phosphorylate cofilin. Cofilin promotes destabilization of stress fibers and its phosphorylation by LIM kinase removes this function\textsuperscript{[45,46]}. In contrast, mammalian diaphanous-related formin activates profilin, which has a counter role to cofilin\textsuperscript{[47]}. In rat podocyte C7 cells, afadin is required for RhoA/ROCK-dependent stress fiber formation, and its depletion leads to downregulation of RhoA/ROCK activity and, consequently, loss of actin stress fibers\textsuperscript{[48]}. In addition to the stabilization of stress fibers, RhoA mediates SMC differentiation by regulating SRF-dependent transcription, which is responsible for the coordinated expression of several smooth muscle-
specific contractile and cytoskeletal genes\textsuperscript{[4]}. The stabilized stress fibers promote the transfer of MRTF-A into the nucleus where it can then associate with SRF to upregulate classical differentiated SMC markers\textsuperscript{[49,50]}. Indeed, the inhibition of either RhoA or ROCK impairs the expression of α-SMA and smooth muscle 22 alpha\textsuperscript{[51]}. 

**Promotion of the synthetic (dedifferentiated) SMC phenotype**

The RhoA/ROCK signaling pathway also promotes dedifferentiation of SMCs through mediating migratory responses to a host of pro-proliferative and pro-migratory stimuli. One of the most well-recognized dedifferentiation stimuli, PDGF-BB, acts in part by activating RhoA. The RhoA/ROCK axis can also be upregulated by pro-synthetic stimuli, such as lysophosphatidic acid\textsuperscript{[52]} and angiotensin II\textsuperscript{[53]}. PDGF-BB upregulates the activation of RhoA, ROCK1 and ROCK2 in rabbit and human aortic vascular SMCs\textsuperscript{[54,55]}. The activation of ROCK1 and ROCK2 is responsible for promoting cell cycle progression via transcriptional regulation of cyclins, whereas ROCK1 alone is responsible for the pro-migratory effect of PDGF-BB. Interestingly, the RhoA pathway also upregulates the expression of PDGF receptor beta to promote persistent dedifferentiation through positive feedback of the PDGF signal\textsuperscript{[55]}. Integrins are transmembrane receptors, which are responsible for linking the cell cytoskeleton to the extracellular matrix, and this accounts for SMC phenotypic changes\textsuperscript{[56]}. Integrin αVβ3 activates RhoA through the tyrosine kinase pathway to mediate directional migration\textsuperscript{[57]}. This integrin is weakly expressed in contractile SMCs, but is activated in response to vitronectin, osteopontin and fibronectin\textsuperscript{[58]}. Because these extracellular matrix proteins can be expressed by synthetic SMCs, this may be another mechanism (in addition to PDGF-BB) that prolongs the dedifferentiated phenotype.

This dual role of RhoA, where it promotes the contractile and synthetic phenotypes, supports the hypothesis that RhoA is a critical regulator of the SMC phenotypic fate, which can be protective against or causative of
vascular disease depending upon its context [Figure 2]. The mechanisms controlling this dedifferentiation and redifferentiation of SMCs are unclear, but several molecular pathways that control SMC modulation are likely to be involved. The involvement of RhoA/ROCK in phenotypic switching could, at least in part, account for redifferentiation and possibly involve a complex interaction between several biomarkers. However, the critical role of RhoA/ROCK in SMC redifferentiation is yet to be fully understood.

**RhoA AND POST-REVASCULARIZATION COMPLICATIONS IN DIABETES**

Patients with T2DM present with microvascular and macrovascular complications [59]. Both of these complications have similar etiological characteristics, and chronic hyperglycemia is an important factor for their initiation. Microvascular complications include nephropathy, neuropathy and retinopathy [60]. The macrovascular complications of T2DM are underpinned by widespread atherosclerotic plaque formation in coronary, carotid, renal, and other large and medium-sized arteries [61]. Diabetes is an independent risk factor for cardiovascular disease. The prevalence of cardiovascular disease in patients with T2DM is 2-4 times higher than that in non-diabetic patients [62]. While intensive glycemic control can reverse microvascular complications fully, this does not occur for macrovascular complications, at least in the medium term [63]. Consequently, many patients with T2DM require surgical intervention to restore adequate blood flow to the heart.

Coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) are used to revascularize the heart. Although PCI is more common, approximately 15,000 CABG surgeries are performed annually in the UK [64]. CABG has lower associated mortality and morbidity risks than PCI [65], and is more beneficial for patients with T2DM and complex vessel disease [66,67]. While only approximately 10% of people have diabetes [68], more than 40% of patients undergoing CABG have T2DM [69]. Therefore, CABG will continue to be a necessity over the coming years. Saphenous vein (SV) grafts have much poorer patency than arterial grafts [70]. However, because of the extensive nature of coronary disease in patients with T2DM, SV grafts are commonly the conduit of choice [71]. Unfortunately, the failure rate of these grafts remains high, and maladaptive histological changes indicate that only 40%-50% of grafts remain patent after 10 years [72,73]. Additionally, diabetes is an independent risk factor for higher mortality of repeat revascularization [74].

**Adaptation and arterialization of vascular grafts**

Following the implantation of SV grafts into the coronary circulation, these grafts must undergo a process of arterialization to withstand the greater mechanical forces and pressure of the myocardium, as opposed to their normal position in the leg. During the first few days post-CABG, dedifferentiation of medial SMCs at the site of anastomoses and intimal injury occurs with an associated increase in proliferative activity [75,76]. Intimal hyperplasia resulting from enhanced proliferative and migratory activity appears to be an initial, adaptive response of a SV graft into the arterial circulation and is positive for graft integration [77,78]. This switch to the synthetic phenotype is also transient, and dedifferentiated SMCs must redifferentiate into the contractile phenotype in a timely manner to form a fully functioning conduit without progressing into maladaptive neointimal hyperplasia [6,76]. Elevated glucose concentrations can induce prenylation and RhoA activity in rodents. However, the implications of this finding for post-bypass adaptation are yet to be studied [79,80].

SMCs from the SV of patients with T2DM show a mixed phenotype that has features of contractile and synthetic cells. SMCs in T2DM tend to have increased levels of α-SMA and miR-145 and a reduced proliferative capacity indicative of contractile SMCs. SMCs in T2DM also have an enlarged rhomboid shape, defective F-actin cytoskeleton and secretory profile, which is suggestive of the synthetic
Figure 2. Regulation of smooth muscle cell phenotypes. Smooth muscle cells usually exist in a contractile differentiated state characterized by expression of contractile proteins, such as α-SMA, SM22-α, calponin and smoothelin. This is regulated by the SRF-myocardin transcription complex in response to extracellular and intracellular cues. Dedifferentiation into a synthetic phenotype is driven by the inhibition of the SRF-myocardin system via KLF4. RhoA and ROCKs play a role in both of these pathways. α-SMA: Alpha smooth muscle actin; ECM: extracellular matrix; GPCR: G protein-coupled receptor; KLF4: Kruppel-like factor 4; LIMK: LIM domain kinase; mDia: mammalian diaphanous-related formin; MLC: myosin light chain; MRTF: myocardin-related transcription factor; NFκB: nuclear factor kappa B; PDGF-BB: platelet-derived growth factor-BB; PDGF-Rβ: platelet-derived growth factor-BB receptor beta; RGS: regulator of G protein signaling; ROCK: Rho kinase; SM22-α: smooth muscle 22 alpha; SRF: serum-response factor; TGFβ: transforming growth factor beta; TGFBRII: transforming growth factor beta receptor two.

Importantly, primary human SV SMCs from patients with T2DM consistently show downregulated RhoA protein and activity levels, which are post-transcriptionally controlled. This finding is specific to the SV because SMCs from arterial conduits (internal mammary artery) have no such impairment[^84]. Internal mammary artery arterial grafts are not prone to the same failure rate as that in the SV. Therefore, the basally-reduced level of RhoA activity in these cells may prevent them from being able to adapt and dynamically switch their phenotype once implanted into coronary vessels.

Atherogenesis and intimal hyperplasia

In the process of atherogenesis, RhoA plays a major role in the modification of SMCs from a contractile to synthetic phenotype, leading to intimal thickening within the walls of the vessel. Studies on the effects of RhoA on macrophage behavior indicated that an increase in plasma cholesterol concentrations interfered with RhoA activation and inhibited macrophage migration, which was related to reduced generation of contractile force in the cells[^85]. This finding provides a possible explanation for lipid-laden cell retention in most atherosclerotic lesions and the likely involvement of RhoA in cellular apoptosis. An elegant murine study examined the contribution of venous and arterial cells to intimal lesions 42 days post-bypass[^86]. This study showed that both SMC sources contributed to intimal formation at the anastomoses, but intimal formation within the middle of the grafts was exclusively derived from the implanted vein. These findings highlight the critical importance of timely redifferentiation within the vein to form an optimally-functioning conduit. RhoA expression and regulation differ in T2DM according to a venous or arterial source[^84], and understanding the activity of RhoA in these scenarios would be beneficial.
Within SV SMCs, the activation of RhoA and ROCKs promote the synthetic phenotype via the orphan G-protein coupled receptor GPR35, which causes an increase in stress fibers and cell length. This situation leads to a subsequent increase in synthetic SMC migratory capacity\cite{87} and contributes to intimal thickening. Interestingly, GPR35 is reportedly anti-inflammatory in the majority of cell types tested\cite{88}, although notably, SMCs have not yet been examined in this regard. The upregulation of RhoA is also essential for the synthesis of RGS5, which is required to promote the synthetic SMC phenotype, and this allows for the structural renovation of the arterial wall\cite{89}.

During atherogenesis, there is an accumulation of various cell types within the vessel wall, which include pericyte-like stellate cells. These cells are found immediately below the endothelial lining\cite{90,91}. Pericytes are structurally similar to SMCs in that they are composed of contractile filaments such as $\alpha$-SMA. Indeed, the shared characteristics between SMCs and pericytes could make the latter susceptible to the interference of RhoA, specifically the GEF1 activator, which is responsible for mediating $\alpha$-SMA\cite{92}. Pericyte-like cells are highly variable and show a flexible phenotype. Therefore, pericyte-like cells are yet to be properly classified, with some studies suggesting that they are an adaptive group of cells, and express markers variably depending on their environment\cite{90}. This attribute causes difficulty in predicting a likely effect of RhoA (de)regulation on these cells and determining how it may compare with classical SMC regulation.

In addition to reduced baseline RhoA activity, SV SMCs in T2DM are exposed to a number of circulating and surrounding factors that provide competing phenotypic cues. Pro-contractile stimuli, such as TGF$\beta$, are enhanced in T2DM\cite{93}. However, in contrast, pro-synthetic extracellular matrix proteins, such as fibronectin and osteopontin, are increased in response to increased advanced glycation end-products and deregulated calcium signaling in T2DM\cite{94,95}.

**RhoA AND STATINS**

Statins are 3-hydroxy-3-methylglutaryl-Coenzyme A reductase inhibitors. They are principally prescribed owing to their cholesterol-lowering ability, but also exhibit beneficial pleiotropic effects, such as improvement of endothelium-dependent vessel relaxation, attenuated atherosclerotic progression and a reduced incidence of heart failure\cite{96}. The mechanisms underpinning these pleiotropic effects are incompletely understood, although they likely involve, at least in part, alteration of RhoA signaling in vascular cells\cite{97}.

The inhibition of the mevalonate pathway (responsible for cholesterol biosynthesis) also inhibits geranylgeranylation and farnesylation, and consequently reduces prenylation of proteins such as RhoA, inhibiting their activity\cite{98}. Fluvastatin blocks lipoprotein(a)-induced RhoA activity in human SMCs, negating the detrimental effects of lipoprotein(a) on vascular remodeling\cite{97}. Similarly, fluvastatin inhibits PDGF-induced proliferation in rodent SMCs via the inhibition of RhoA, preventing transition to a synthetic phenotype and aberrant vascular remodeling\cite{99}. Simvastatin treatment permanently impairs adrenergic $\alpha$-agonist-induced contractility through the blockade of voltage-operated calcium channels and the inhibition of RhoA-induced myosin light chain phosphorylation\cite{100}. While these signalling events are all conceptually beneficial for vessel function by promoting vasodilation and reducing remodeling, they also possess undesirable effects. Simvastatin promotes SMC apoptosis and reduces the lumen area\cite{100}, which is associated with cytoskeletal integrity. The pro-apoptotic factor Bmf is usually sequestered on stable actin fibers. When statin use impairs RhoA, this reduces the stability of actin fibers, and Bmf is released and translocated to the mitochondria and then induces an apoptotic cascade\cite{101}.
Implications for statin use in patients with T2DM

The importance of statins is intimately associated with the vascular complications of T2DM. As discussed above, animal studies have shown that hyperglycemia increases RhoA activity and upregulates SMC proliferation, and this is abrogated by pitavastatin treatment[79]. This finding suggests a positive role for statins in SMC hyperproliferative disorders caused by T2DM (e.g., neointimal hyperplasia and atherosclerosis). However, in human SV SMCs, there is an inherent inhibition of RhoA activity in unstimulated T2DM cells[84]. This would conceivably be reduced even further if these patients were treated with statins. The cumulative inhibition of RhoA through combining T2DM with statin use may explain why SV grafts in patients with T2DM still have such a poor patency rate, and is worthy of further investigation.

One controversial consequence of prolonged statin use is an increased risk of developing new-onset T2DM by 10%-45%[102]. This occurs via a two-pronged attack whereby certain statins cause pancreatic β-cell dysfunction through the inhibition of L-type calcium channels and glucose transporter 2 translocation, thus impairing insulin release. In parallel, statins increase insulin resistance through inhibiting insulin receptor substrate-1 and glucose transporter 4 translocation in peripheral tissues[97]. Notably, the relative cardiovascular benefit of statins outweighs the risk of new-onset diabetes[103]. However, the prescription of statins for secondary preventative care in patients who are already at a high risk of developing T2DM may facilitate its development, and the consequent cardiovascular-associated T2DM morbidity and mortality.

CONCLUSIONS

The healthcare and socioeconomic costs of escalating T2DM cannot be underestimated. While there have been major breakthroughs in restoring glycemic control and managing T2DM over the last few decades, macrovascular complications persist. Therefore, understanding the molecular pathways that affect the blood vessels of these patients is of utmost importance. The benefits of statins for cardiovascular patients are well recognized, but controversy still surrounds their widespread use. Because of the critical role that RhoA plays in SMC phenotypic switching, surprisingly, there have been no clinical studies regarding its potential as a therapeutic target. Therefore, these studies need to be performed to progress the field. The evidence discussed in this review highlights the important role of RhoA in maintaining the sensitivity of SMCs to respond to de/differentiation cues, and the downstream effects that this has on SMC function, and thus vascular health. We suggest that further research examining this role will link molecular, cellular and vascular changes and identify areas for intervention. Further research on the pleiotropic inhibition of RhoA activity by statins in patient groups where RhoA is already impaired is required. These studies are important to establish if additional therapies restoring RhoA in SMCs, especially in implanted coronary conduits, could improve revascularization outcomes.

DECLARATIONS

Authors’ contributions
Conceptualized the article: Riches-Suman K
Both authors contributed equally to the content of the article.

Availability of data and materials
Not applicable.

Financial support and sponsorship
Asare-Amankwah Y is supported by the Ghana Scholarships Secretariat.
Conflicts of interest
Both authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES


80. Chen GP, Zhang XQ, Wu T, Li L, Han J, Du CQ. Alteration of mevalonate pathway in proliferated vascular smooth muscle from
90. Ivanova EA, Bobryshev YV, Orekhov AN. Intimal pericytes as the second line of immune defence in atherosclerosis. World J Cardiol 2015;7:583-93. DOI PubMed PMC
97. Patel KK, Sehgal VS, Kashfi K. Molecular targets of statins and their potential side effects: Not all the glitter is gold. Eur J Pharmacol 2022;922:174906. DOI PubMed PMC